{
    "root": "3622ca24-c93a-c2af-e063-6394a90a1a41",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Quetiapine",
        "suffix": {
            "text": "Extended Release"
        }
    },
    "value": "20250523",
    "ingredients": [
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "QUETIAPINE FUMARATE",
            "code": "2S3PL1B6UJ"
        }
    ],
    "indications": "quetiapine extended-release tablets atypical antipsychotic indicated treatment : schizophrenia ( 1.1 ) bipolar disorder , manic mixed episodes ( 1.2 ) bipolar disorder , depressive episodes ( 1.2 ) major depressive disorder , adjunctive therapy antidepressants ( 1.3 )",
    "contraindications": "swallow tablets whole split , chew crush ( 2.1 ) take without food light meal ( approx . 300 calories ) ( 2.1 ) administer daily , preferably evening ( 2.1 ) geriatric : consider lower starting dose ( 50 mg/day ) , slower titration , careful monitoring initial dosing period elderly . ( 2.3 , 8.5 ) hepatic impairment : lower starting dose ( 50 mg/day ) slower titration may needed ( 2.4 , 8.7 , 12.3 ) indication initial dose recommended dose maximum dose schizophrenia-adults ( 2.2 ) 300 mg/day 400 800 mg/day 800 mg/day schizophrenia-adolescents ( 13 17 years ) ( 2.2 ) 50 mg/day 400 800 mg/day 800 mg/day bipolar disorder manic mixed-acute monotherapy adjunct lithium divalproex-adults ( 2.2 ) 300 mg/day 400 800 mg/day 800 mg/day bipolar disorder , manic acute monotherapy-children adolescents ( 10 17 years ) ( 2.2 ) 50 mg/day 400 600 mg/day 600 mg/day bipolar disorder , depressive episodes-adults ( 2.2 ) 50 mg/day 300 mg/day 300 mg/day major depressive disorder , adjunctive therapy antidepressants-adults ( 2.2 ) 50 mg/day 150 300 mg/day 300 mg/day",
    "warningsAndPrecautions": "200 mg tablets yellow , film coated , capsule-shaped , biconvex embossed tablet “ 382 ” one side plain supplied ndc 60760-866-30 bottles 30 store quetiapine extended-release tablets 25ºc ( 77ºf ) ; excursions permitted 15ºc 30ºc ( 59ºf 86ºf ) [ usp controlled room temperature ] .",
    "adverseReactions": "hypersensitivity quetiapine excipients quetiapine extended-release tablets formulation . anaphylactic reported patients treated quetiapine extended-release tablets .",
    "indications_original": "Quetiapine extended-release tablets are an atypical antipsychotic indicated for the treatment of: Schizophrenia (1.1) Bipolar I disorder, manic or mixed episodes (1.2) Bipolar disorder, depressive episodes (1.2) Major depressive disorder, adjunctive therapy with antidepressants (1.3)",
    "contraindications_original": "Swallow tablets whole and do not split, chew or crush (2.1) Take without food or with a light meal (approx. 300 calories) (2.1) Administer once daily, preferably in the evening (2.1) Geriatric Use: Consider a lower starting dose (50 mg/day), slower titration, and careful monitoring during the initial dosing period in the elderly. ( 2.3 , 8.5 ) Hepatic Impairment: Lower starting dose (50 mg/day) and slower titration may be needed ( 2.4 , 8.7 , 12.3 ) Indication Initial Dose Recommended Dose Maximum Dose Schizophrenia-Adults (2.2) 300 mg/day 400 to 800 mg/day 800 mg/day Schizophrenia-Adolescents (13 to 17 years) (2.2) 50 mg/day 400 to 800 mg/day 800 mg/day Bipolar I Disorder manic or mixed-Acute monotherapy or adjunct to lithium or divalproex-Adults (2.2) 300 mg/day 400 to 800 mg/day 800 mg/day Bipolar I Disorder, manic Acute monotherapy-Children and Adolescents (10 to 17 years) (2.2) 50 mg/day 400 to 600 mg/day 600 mg/day Bipolar Disorder, Depressive Episodes-Adults (2.2) 50 mg/day 300 mg/day 300 mg/day Major Depressive Disorder, Adjunctive Therapy with Antidepressants-Adults (2.2) 50 mg/day 150 to 300 mg/day 300 mg/day",
    "warningsAndPrecautions_original": "200 mg Tablets yellow, film coated, capsule-shaped, biconvex embossed tablet with “382” on one side and plain on the other are supplied in\n                  \n                  \n                  NDC 60760-866-30 BOTTLES OF 30\n                  \n                  Store quetiapine extended-release tablets at 25ºC (77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Hypersensitivity to quetiapine or to any excipients in the quetiapine extended-release tablets formulation. Anaphylactic reactions have been reported in patients treated with quetiapine extended-release tablets."
}